In another genomic study of BM of various origin, several potentially actionable genomic alterations were associated with lung cancer BM, including AKT1, AURKA, CDK6, EGFR, MEK1, MET, and PIK3CA gene amplifications and CDKN2A deletions.8 This evidence concerns the gene MAP2K1 and lung carcinoma.